Vaccine therapy + dasatinib for the treatment of patients with stage IIIB-IV melanoma

Ahmad A Tarhini; Hussein Tawbi; Walter J Storkus

doi:10.2217/mmt-2016-0016

Vaccine therapy + dasatinib for the treatment of patients with stage IIIB-IV melanoma

Melanoma Manag. 2016 Dec;3(4):251-254. doi: 10.2217/mmt-2016-0016. Epub 2016 Nov 29.

Authors

Ahmad A Tarhini^{1

2

1

2}, Hussein Tawbi^{3

3}, Walter J Storkus^{2

4

5

6

7

2

4

5

6

7}

Affiliations

¹ Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
² Melanoma Program of the University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.
³ Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
⁴ Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
⁵ Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
⁶ Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
⁷ Department of Bioengineering, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

No abstract available

Keywords: T-cells receptor; adjuvant; dasatinib; dendritic cells; immunotherapy; melanoma; tumor microenvironment; tyrosine kinase inhibitors; vaccine.

Publication types

Editorial

Publication types

Grants and funding